RNA Analytical/Quality Videos

  1. What Learnings Can mRNA Take From The Oligonucleotide Regulatory Paradigm? 5/10/2024

    ReciBioPharm’s Melanie Cerullo shares where mRNA needs to “catch up” to its oligonucleotide “cousin” molecules and where regulatory differences may be emerging between modalities.

  2. Why We Still Haven't Solved mRNA Scale-Up 10/15/2025

    While we can make lots of mRNA at a smaller scale, when it comes to scaling up to kg quantities of mRNA, our current batch processes leave a lot to be desired. Together, Stu Sundseth of Tune Therapeutics and Christian Dohmen of Ethris unpack the biggest barriers to scaling IVT to achieve the desired yield and quality of mRNA, offering their take on how the field is innovating to overcome these issues. 

  3. The Conjugation Conundrum: The Realities Of Conjugated LNP Manufacturing 2/24/2026

    In this Advancing RNA Live clip, CMC Consultant Sujit Jain explains the numerous ways that adding targeting ligands “stress tests” the standard LNP manufacturing platform, as well as outlines which capabilities are most important for companies to consider when selecting an outsourcing partner for their active delivery strategies.

  4. Goldilocks & The Guidances: Finding "Just Right" For RNA Regulations 6/24/2025

    Do we need more specific regulatory guidance for every RNA modality and therapeutic approach? We asked and the Advancing RNA Live audience answered… Here, panelists Tiffany Lucas and Ulrike Jägle address the audience’s responses, as well as share their thoughts on just how prescriptive the future of regulatory guidance for RNA therapeutics approaches could/should be..

  5. RNA Interference - From Single Gene Studies To Whole Genome Screens 11/7/2022

    Endoribonuclease-prepared siRNAs (esiRNAs) are able to overcome the limitations of RNAi. Learn about esiRNAs, their advantages over standard siRNAs, and ways this technology is utilized in different research fields.

  6. Primates, Patents, And Progress: Advancements In Rational LNP Design 2/24/2026

    In this opening Advancing RNA Live clip, NanoVation Therapeutics’ Dominik Witzigmann and Stealth Co’s John Zuris share the scientific advancements they’ve been watching most keenly in the LNP space, as well as some of the evolutions they’re seeing in the overall quality of our RNA-LNP products.

  7. Webinar Teaser: LBA Vs. LC-MS 2/6/2025

    Why are so many sponsors shifting from Ligand-Binding Assays (LBA) to Liquid Chromatography-Mass Spectrometry (LC-MS) for large molecule protein analysis?

  8. Taming dsRNA Via Innovation In The Supply Chain 10/15/2025

    Here, Ethris’ Christan Dohmen and Tune Therapeutics’ Stu Sundseth share their take on the most meaningful strategies for reducing dsRNA production. But this discussion also probes a deeper question: Is dsRNA still the most relevant impurity the industry should be chasing, or should focus shift to other contaminants? 

  9. Validation Of mRNA Concentration Determination 8/20/2023

    mRNA-based therapeutics require comprehensive analytical testing to meet regulatory requirements. Optimize processes and ensure fast and reliable results as you bring your product to market.

  10. Best Practices In Aseptic Sampling To Improve Quality In Bioprocessing 5/30/2024

    Learn about the key aspects of aseptic sampling, appropriate methods and circumstances to perform sampling, and the impact a platform and sample containers can have on assay results and process dynamics.